ZENTALIS PHARMACEUTICALS

Contributing Author

Recent Articles by ZENTALIS PHARMACEUTICALS

Jun-01	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
May-27	Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy ZNTL GlobeNewswire
May-21	Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 ZNTL +11.59% GlobeNewswire
May-13	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences ZNTL GlobeNewswire
May-12	Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress ZNTL GlobeNewswire
May-05	Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer ZNTL GlobeNewswire
May-01	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
Apr-21	Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer ZNTL GlobeNewswire
Apr-17	Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 ZNTL -13.15% ZNTL -7.57% GlobeNewswire
Apr-09	Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer ZNTL +60.14% GlobeNewswire
Apr-01	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL +9.83% GlobeNewswire
Mar-26	Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates ZNTL -21.35% ZNTL GlobeNewswire
Mar-17	Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 ZNTL -7.88% ZNTL GlobeNewswire
Feb-18	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences ZNTL GlobeNewswire
Feb-03	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference ZNTL +12.35% ZNTL -9.57% GlobeNewswire
Jan-06	Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 ZNTL +29.93% GlobeNewswire
Nov-10	Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress ZNTL +6.06% ZNTL GlobeNewswire
Nov-03	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL -8.33% ZNTL GlobeNewswire
Nov-03	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences ZNTL GlobeNewswire
Oct-13	Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ZNTL GlobeNewswire
Oct-01	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL +7.79% ZNTL GlobeNewswire
Sep-02	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
Aug-28	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences ZNTL GlobeNewswire
Aug-26	Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary ZNTL GlobeNewswire
Aug-06	Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress ZNTL +5.07% ZNTL GlobeNewswire
Jul-01	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
Jun-02	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL +6.25% ZNTL +5.79% GlobeNewswire
May-14	Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress ZNTL +5.88% ZNTL GlobeNewswire
May-01	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire

ZENTALIS PHARMACEUTICALS

Recent Articles by ZENTALIS PHARMACEUTICALS

Upgrade your Finviz experience